Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT00982280
Other study ID # 847022
Secondary ID 2009-010425-39
Status Terminated
Phase Phase 3
First received
Last updated
Start date September 2009
Est. completion date August 2010

Study information

Verified date October 2019
Source Grünenthal GmbH
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The main objective of the study is to evaluate the effectiveness, tolerability, and safety of tapentadol hydrochloride prolonged release (PR) in participants suffering from severe chronic pain due to osteoarthritis of the knee who are taking WHO Step III analgesics and show lack of tolerability. This is a clinical effectiveness trial designed to establish a link between anticipated clinical outcomes and the clinical practice by means of selected measures of clinical and subject-reported outcome. The trial will compare the effectiveness of previous analgesic treatment (WHO Step III) with that of tapentadol hydrochloride PR treatment during defined periods of evaluation.


Description:

The trial will last up to 13 weeks for each subject and includes:

- One week of observation under previous analgesic treatment.

- Twelve weeks of treatment with tapentadol hydrochloride PR.


Recruitment information / eligibility

Status Terminated
Enrollment 82
Est. completion date August 2010
Est. primary completion date May 2010
Accepts healthy volunteers No
Gender All
Age group 40 Years and older
Eligibility Inclusion Criteria:

- Participants must have signed an Informed Consent Form indicating that they understand the purpose of and procedures required for the trial and are willing to participate in it.

- Participants are men or non-pregnant, non-lactating women. Sexually active women must be postmenopausal, surgically sterile, or practicing an effective method of birth control (e.g., prescription oral contraceptives, contraceptive injections, intrauterine device, double barrier method, contraceptive patch, male partner sterilization) before entry and throughout the trial. Women of childbearing potential must have a negative pregnancy test at screening.

- Participants must be appropriately communicative to verbalize and to differentiate with regard to location and intensity of the pain.

- Participants must be at least 40 years of age.

- Participants must have a diagnosis of osteoarthritis of the knee based on the American College of Rheumatology (ACR) Classification criteria:

- Knee pain and

- Radiographic osteophytes or

- Knee pain and aged 40 years or above and

- Morning stiffness of less than 30 minutes of duration and

- Crepitus on motion.

- Participants must have pain at the reference joint which has been present for at least 3 months.

- Participant's pain must require a strong analgesic (defined as WHO Step III) as judged by the Investigator

- Participant must be taking a WHO Step III analgesic on a daily basis for at least 2 weeks prior to the Screening Visit.

- Participant must have responded to the WHO Step III analgesic, i.e., participant must have a confirmed average pain intensity score (NRS 3) of smaller or equal to 5 points during the last 3 days prior to the Screening Visit.

- Participant must report opioid-related side effects as the reason to change their analgesic

- Participant must report a rate of satisfaction with their previous analgesic regimen not exceeding "fair" on a subject satisfaction with treatment scale (5-point VRS).

Exclusion Criteria:

- Presence of a clinically significant disease or laboratory findings that in the Investigator's opinion may affect efficacy or safety assessments.

- Presence of active systemic or local infection that may, in the opinion of the Investigator, affect the efficacy, quality of life/function or safety assessments.

- History of alcohol or drug abuse, or suspicion thereof in Investigator's judgement.

- Presence of concomitant autoimmune inflammatory conditions.

- Known history of or laboratory values reflecting severe renal impairment.

- Known history of moderately or severely impaired hepatic function.

- History of or active hepatitis B or C within the past 3 months or history of HIV infection.

- History of seizure disorder or epilepsy.

- Any of the following within 1 year: mild/moderate traumatic brain injury, stroke, transient ischemic attack, or brain neoplasm. Severe traumatic brain injury within 15 years (consisting of 1 or more of the following: brain contusion, intracranial hematoma, either unconsciousness or post traumatic amnesia lasting more than 24 h) or residual sequelae suggesting transient changes in consciousness.

- Pregnant or breast-feeding.

- History of allergy to, or hypersensitivity to tapentadol hydrochloride or its excipients, or contraindications related to tapentadol hydrochloride including:

- participants with acute or severe bronchial asthma or hypercapnia.

- participants who have or are suspected of having paralytic ileus.

- Employees of the Investigator or trial site, with direct involvement in this trial or other trials under the direction of the Investigator or trial site, as well as family members of employees of the Investigator.

- Participation in another trial concurrently or within 4 weeks prior to the Screening Visit.

- Known to or suspected of not being able to comply with the protocol and the use of the investigational medicinal product.

- Use of monoamine oxidase inhibitors within 14 days before the Screening Visit.

- Non-stable dosing of selective serotonin reuptake inhibitors within 30 days before the Screening Visit (the doses must remain stable during the trial).

- Osteoarthritis in a flare state.

- Use of intra-articular injections of hyaluronic acid in the reference joint within 3 months before the Screening Visit.

- Presence of conditions other than OA of the reference joint that could confound the assessment or self-evaluation of pain, e.g., anatomical deformities, significant skin conditions such as abscess or syndromes with widespread pain such as fibromyalgia. Subjects with OA at joints other than the reference joint will not be excluded as long as the reference joint is the source of main pain and disability.

- History and clinical signs at the reference joint of crystal-induced (e.g., gout, pseudo-gout), metabolic, infectious and autoimmune disease.

- Any painful procedures during the trial (e.g., major surgery including the reference joint) that may, in the opinion of the Investigator, affect the efficacy or safety assessments.

- Pending litigation due to chronic pain or disability.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Tapentadol PR
Tapentadol Prolonged Release (PR) Titration and Optimal Dose Period: Starting at 50 mg, 100 mg or 150 mg Tapentadol PR twice daily, adjusting at 50 mg PR steps (upwards or downwards) as necessary to achieve a balance between pain relief and a satisfactory level of tolerability. Participants were not permitted to exceed 500 mg of Tapentadol per day. Maintenance Period: Participants continuing on the dose established in the previous period.

Locations

Country Name City State
Australia Site 4 Melbourne
Australia Site 2 Perth
Denmark Site 4 Aalborg
Denmark Site 7 Hvidovre
Denmark Site 6 Kolding
Denmark Site 2 Odense
Denmark Site 3 Vejle
Germany Site 1 Berlin
Germany Site 7 Katzhütte
Germany Site 2 Leer
Germany Site 8 Leipzig
Germany Site 9 Zerbst
Poland Site 4 Lublin
Poland Site 5 Ostrow Mazowiecka
Poland Site 2 Tychy
Spain Site 4 Madrid
Spain Site 1 Valencia
United Kingdom Site 3 Birmingham
United Kingdom Site 6 Carmarthen
United Kingdom Site 1 Leeds
United Kingdom Site 2 London
United Kingdom Site 8 Middlesborough
United Kingdom Site 9 Oxford
United Kingdom Site 10 York

Sponsors (1)

Lead Sponsor Collaborator
Grünenthal GmbH

Countries where clinical trial is conducted

Australia,  Denmark,  Germany,  Poland,  Spain,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Responder Rate Participants were considered responders if they reported the same or less average pain intensity over a 3 day period after 6 weeks of tapentadol PR treatment as with their previous analgesic treatment. 6 weeks
Secondary Average Pain Intensity Before the Start of Tapentadol Treatment For this pain assessment, the participant was to indicate the level of average pain experienced over the previous 3 days on an 11-point Numerical Rating Scale(NRS) where a score of 0 indicated "no pain" and a score of 10 indicated "pain as bad as you can imagine". Baseline
Secondary Change in Average Pain Intensity After 6 Weeks of Tapentadol PR Treatment. For this pain assessment, the participant was to indicate the level of average pain experienced over the previous 3 days on an 11-point Numerical Rating Scale(NRS) where a score of 0 indicated "no pain" and a score of 10 indicated "pain as bad as you can imagine". The value indicates the change from the baseline value on the 0 to 10 scale. A Negative value indicates a reduction in pain intensity from the baseline average pain intensity. Baseline; Week 6 (6 weeks)
Secondary Change in Average Pain Intensity After 12 Weeks of Tapentadol PR Treatment. For this pain assessment, the participant was to indicate the level of average pain experienced over the previous 3 days on an 11-point Numerical Rating Scale(NRS) where a score of 0 indicated "no pain" and a score of 10 indicated "pain as bad as you can imagine". The value indicates the change from the baseline value on the 0 to 10 scale. A Negative value indicates a reduction in pain intensity from the baseline average pain intensity. Baseline; Week 12 (12 weeks)
Secondary Baseline Western Ontario McMaster Questionnaire (WOMAC) Global Score Assessing Pain, Disability and Joint Stiffness of the Knee Western Ontario McMaster Questionnaire (WOMAC) Global Score: WOMAC is measured with a Likert ordinal scale (the participant gives one of 5 possible answers) A higher score indicate that a symptom is bothersome or disabling. The WOMAC is a self-administered questionnaire and has 24 questions: Pain, Stiffness and Physical Function. The possible scores range from 0-20 for pain, 0-8 for stiffness, 0-68 for physical function and these are then summed 0-96 for the global score. A lower score indicates a lower level of symptoms and or disability. Baseline
Secondary Change From Baseline in the Western Ontario McMaster Questionnaire (WOMAC) Global Score Assessing Pain, Disability and Joint Stiffness of the Knee Over the Last Week at Week 6 The WOMAC is a self-administered questionnaire and has 24 questions: Pain, Stiffness and Physical Function. The possible scores range from 0-20 for pain, 0-8 for stiffness, 0-68 for physical function and these are then summed 0-96 for the global score. The negative value indicates that there has been an improvement since baseline, the higher the value the greater the change since baseline. 6 weeks
Secondary Change From Baseline in the Western Ontario McMaster Questionnaire (WOMAC) Global Score Assessing Pain, Disability and Joint Stiffness of the Knee Over the Last Week at Week 12 The WOMAC is a self-administered questionnaire and has 24 questions: Pain, Stiffness and Physical Function. The possible scores range from 0-20 for pain, 0-8 for stiffness, 0-68 for physical function and these are then summed 0-96 for the global score. The negative value indicates that there has been an improvement since baseline, the higher the value the greater the change since baseline. 12 weeks
Secondary EuroQol-5 (EQ-5D) Health Status Index Outcome Over Time The participant scored the EuroQol-5. This is a five dimensional health state classification. Each dimension is assessed on a 3-point ordinal scale (1=no problems, 2=some problems, 3=extreme problems). The responses to the five EQ-5D dimensions were scored using a utility-weighted algorithm to derive an EQ-5D health status index score between 0 to 1, with 1.00 indicating "full health" and 0 representing dead. The positive values indicate that during the study the health status improved. 6 weeks
Secondary EuroQol-5 (EQ-5D) Health Status Index Outcome Over Time The participant scored the EuroQol-5. This is a five dimensional health state classification. Each dimension is assessed on a 3-point ordinal scale (1=no problems, 2=some problems, 3=extreme problems). The responses to the five EQ-5D dimensions were scored using a utility-weighted algorithm to derive an EQ-5D health status index score between 0 to 1, with 1.00 indicating "full health" and 0 representing dead. The positive values indicate that during the study the health status improved. 12 weeks
Secondary Change in Health Related Quality of Life: EuroQol-5D Health State Visual Analog Scale (VAS) EuroQoL-5D Health State Visual Analog Scale (VAS) is a participant rated questionnaire to assess health-related quality of life in terms of a single index value. The VAS component rates current health state on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state); higher scores indicate a better health state. The values indicated represent the change from the baseline, a positive value indicates an improvement. 6 Weeks
Secondary Change in Health Related Quality of Life: EuroQol-5D Health State Visual Analog Scale (VAS) EuroQoL-5D Health State Visual Analog Scale (VAS) is a participant rated questionnaire to assess health-related quality of life in terms of a single index value. The VAS component rates current health state on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state); higher scores indicate a better health state. The values indicated represent the change from the baseline, a positive value indicates an improvement. 12 Weeks
Secondary Clinical Global Impression of Change In the Clinical Global Impression of Change (CGIC) the clinician indicates the perceived change over the treatment period. The clinician is requested to choose one of seven categories. Scores range from very much improved to very much worse. Baseline; End of Week 6 (6 Weeks)
Secondary Clinical Global Impression of Change In the Clinical Global Impression of Change (CGIC) the clinician indicates the perceived change over the treatment period. The clinician is requested to choose one of seven categories. Scores range from very much improved to very much worse. Baseline; End of Week 12 (12 Weeks)
Secondary Patient Global Impression of Change In the Patient Global Impression of Change (PGIC) the participant indicates the perceived change over the treatment period. The participant is requested to choose one of seven categories. Scores range from very much improved to very much worse. Baseline; End of Week 6 (6 Weeks)
Secondary Patient Global Impression of Change In the Patient Global Impression of Change (PGIC) the participant indicates the perceived change over the treatment period. The participant is requested to choose one of seven categories. Scores range from very much improved to very much worse. Baseline; End of Week 12 (12 Weeks)
Secondary Participant's Satisfaction With Previous Analgesic Treatment. Participants were requested to rate their previous analgesic medication on a 5-point scale. Previous medication was rated as excellent, very good, good, fair and poor. Baseline
Secondary Participant's Satisfaction With New Analgesic Treatment, i.e Tapentadol. Participants were requested to rate their tapentadol (new) analgesic medication on a 5-point scale. The medication was rated as excellent, very good, good, fair and poor. After 6 weeks
Secondary Participant's Satisfaction With New Analgesic Treatment, i.e Tapentadol. Participants were requested to rate their tapentadol (new) analgesic medication on a 5-point scale. The medication was rated as excellent, very good, good, fair and poor. After 12 weeks
Secondary Mean Equipotency Ratio of Tapentadol Compared to Buprenorphine Tapentadol was compared to Transdermal Buprenorphine with Buprenorphine set to 1. The average total daily dose of Tapentadol at which a pain score equivalent or below to the pain score at the end of observation period under Transdermal Buprenorphine was reached was documented as the equipotent or equianalgesic dose to the total daily dose of the previously used Transdermal Buprenorphine. Baseline; End of Week 6 (6 Weeks)
Secondary Mean Equipotency Ratio of Tapentadol Compared to Oxycodone Tapentadol was compared to Oxycodone with Oxycodone set to 1. The average total daily dose of Tapentadol at which a pain score equivalent or below to the pain score at the end of observation period under Oxycodone was reached was documented as the equipotent or equianalgesic dose to the total daily dose of the previously used Oxycodone. Baseline; End of Week 6 (6 Weeks)
See also
  Status Clinical Trial Phase
Completed NCT01659073 - Using Perfusion MRI to Measure the Dynamic Changes in Neural Activation Associated With Caloric Vestibular Stimulation N/A
Recruiting NCT05914311 - Use of Dermabond in Mitigation of Spinal Cord Stimulation (SCS) Trial Lead Migration N/A
Recruiting NCT05422456 - The Turkish Version of Functional Disability Inventory
Enrolling by invitation NCT05422443 - The Turkish Version of Pain Coping Questionnaire
Completed NCT05057988 - Virtual Empowered Relief for Chronic Pain N/A
Completed NCT04385030 - Neurostimulation and Mirror Therapy in Traumatic Brachial Plexus Injury N/A
Recruiting NCT06206252 - Can Medical Cannabis Affect Opioid Use?
Completed NCT05103319 - Simultaneous Application of Ketamine and Lidocaine During an Ambulatory Infusion Therapy as a Treatment Option in Refractory Chronic Pain Conditions
Completed NCT03687762 - Back on Track to Healthy Living Study N/A
Completed NCT04171336 - Animal-assisted Therapy for Children and Adolescents With Chronic Pain N/A
Completed NCT03179475 - Targin® for Chronic Pain Management in Patients With Spinal Cord Injury Phase 4
Completed NCT03418129 - Neuromodulatory Treatments for Pain Management in TBI N/A
Completed NCT03268551 - MEMO-Medical Marijuana and Opioids Study
Recruiting NCT06060028 - The Power of Touch. Non-Invasive C-Tactile Stimulation for Chronic Osteoarthritis Pain N/A
Recruiting NCT06204627 - TDCS* and Laterality Trainnning in Patients With Chronic Neck Pain N/A
Completed NCT05496205 - A SAD Study to Evaluate the Safety, Tolerability and PK/PD of iN1011-N17 in Healthy Volunteers Phase 1
Completed NCT00983385 - Evaluation of Effectiveness and Tolerability of Tapentadol Hydrochloride in Subjects With Severe Chronic Low Back Pain Taking Either WHO Step I or Step II Analgesics or no Regular Analgesics Phase 3
Recruiting NCT05118204 - Randomized Trial of Buprenorphine Microdose Inductions During Hospitalization Phase 4
Terminated NCT03538444 - Repetitive Transcranial Magnetic Stimulation for Opiate Use Disorder N/A
Not yet recruiting NCT05812703 - Biometrics and Self-reported Health Changes in Adults Receiving Behavioral Treatments for Chronic Pain